JNJ
173.89
+0.19%↑
ABBV
198.28
+0.11%↑
AZN
74.06
+0.64%↑
NVS
118.5
+1.46%↑
ABT
131.52
-2.16%↓
JNJ
173.89
+0.19%↑
ABBV
198.28
+0.11%↑
AZN
74.06
+0.64%↑
NVS
118.5
+1.46%↑
ABT
131.52
-2.16%↓
JNJ
173.89
+0.19%↑
ABBV
198.28
+0.11%↑
AZN
74.06
+0.64%↑
NVS
118.5
+1.46%↑
ABT
131.52
-2.16%↓
JNJ
173.89
+0.19%↑
ABBV
198.28
+0.11%↑
AZN
74.06
+0.64%↑
NVS
118.5
+1.46%↑
ABT
131.52
-2.16%↓
JNJ
173.89
+0.19%↑
ABBV
198.28
+0.11%↑
AZN
74.06
+0.64%↑
NVS
118.5
+1.46%↑
ABT
131.52
-2.16%↓
24h
Current
Min
Max
Income | 33M -3.1M |
---|---|
Sales | 8.4M 20M |
Profit margin | -15.19 |
Employees | 59 |
EBITDA | 18M 1.7M |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +86.61% upside |
Next Earnings | 12 sie 2025 |
---|
Market Cap | 190M 615M |
---|---|
Previous open | 0 |
Previous close | 0 |
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
27 lut 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 22.43 USD 86.61%
High 29 USD
Low 12 USD
Based on 8 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
8 ratings
7
Buy
1
Hold
0
Sell
Based on 8 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$